NGM Biopharmaceuticals

NGM Biopharmaceuticals

http://www.ngmbio.com/
Tags:BioTechDevelopmentDrugEngineeringHealthHumanInterestMarketMedicalMedTechPlatformResearch
We are a clinical stage biopharmaceutical company advancing a robust pipeline of drug candidates to address a spectrum of large, unmet medical needs. We are focused on harnessing powerful, untapped biology underlying major diseases to develop transformative therapeutics for patients. Our initial R&D focus has been to develop a portfolio of high-impact therapeutics for the underserved patient populations who suffer from cardio-metabolic and liver diseases. We believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of other disease areas as well, such as cancer. NGM Bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. As we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. Coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. All of NGM Bio’s clinical candidates are first-in-class therapies and several are modulating targets or pathways that were first identified by NGM Bio.
Location: United States, California, South San Francisco
Member count: 201-500
Total raised: $101M
Founded date: 2008

Investors 4

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
18.07.2013Series C$50M-vcnewsdail...
15.03.2010Series B$51M-finsmes.co...

Mentions in press and media 28

DateTitleDescriptionCategoryAuthorSource
20.04.2022NGM Bio to...SOUTH SAN FRANCISCO, Calif., A...--globenewsw...
08.04.2022NGM Bio to...ILT2, ILT4, ILT3 and LAIR1 are...--globenewsw...
08.04.2022NGM Bio to...ILT2, ILT4, ILT3 and LAIR1 are...--globenewsw...
31.03.2022NGM Bio An...Dose-escalation and dose-expan...--globenewsw...
31.03.2022NGM Bio An...Dose-escalation and dose-expan...--globenewsw...
21.03.2022NGM Bio to...--The four-part series titled ...--globenewsw...
10.01.2022NGM Bio Ou...After a transformative year in...--globenewsw...
10.01.2022NGM Biopha...TM Biology-driven discovery. ...--marketscre...
10.01.2022NGM Biopha...TM Biology-driven discovery. ...--marketscre...
06.12.2021NGM Bio An...NGM entered into a clinical tr...--globenewsw...
Show more